Bicycle Therapeutics plcBCYCNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank13
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P13
Within normal range
vs 3Y Ago
-1.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -17.74% |
| Q2 2025 | 20.27% |
| Q1 2025 | 18.64% |
| Q4 2024 | 3.13% |
| Q3 2024 | 20.48% |
| Q2 2024 | 14.90% |
| Q1 2024 | -22.00% |
| Q4 2023 | 12.11% |
| Q3 2023 | 0.37% |
| Q2 2023 | 23.31% |
| Q1 2023 | 30.31% |
| Q4 2022 | 8.65% |
| Q3 2022 | 14.60% |
| Q2 2022 | 38.99% |
| Q1 2022 | 10.25% |
| Q4 2021 | 23.24% |
| Q3 2021 | -10.31% |
| Q2 2021 | 20.93% |
| Q1 2021 | -25.99% |
| Q4 2020 | 77.88% |
| Q3 2020 | -7.48% |
| Q2 2020 | -18.05% |
| Q1 2020 | 15.63% |
| Q4 2019 | 38.17% |
| Q3 2019 | -7.02% |
| Q2 2019 | 4.16% |
| Q1 2019 | -3.34% |
| Q4 2018 | 15.08% |
| Q3 2018 | 14.74% |
| Q2 2018 | 32.57% |
| Q1 2018 | -46.85% |
| Q4 2017 | 0.00% |